伊贝沙坦治疗原发性高血压的临床疗效及安全性观察  

The Clinical Curative Effect and Safety for Irbesartan on Essential Hypertension

作　　者：胡昌菊 胡世鸣 

机构地区：[1]四川省攀枝花市铁路医院,617064

出　　处：《中国医药指南（学术版）》2008年第13期30-32,共3页Guide of China Medicine

摘　　要：目的评价伊贝沙坦治疗原发性高血压的有效性和安全性。方法采用随机、对照法观察伊贝沙坦治疗原发性高血压8周的疗效。70例原发性高血压患者随机分为两组,分别服用伊贝沙坦或非洛地平8周。观察血压变化及不良反应。结果两组治疗前后收缩压、舒张压的下降均有显著性差异(P<0.01),伊贝沙坦组有效率为74.3%,非洛地平组有效率为71.4%,组间比较差异无显著性(P>0.05)。两组治疗前后心率及各项实验室检测结果无显著性变化。结论伊贝沙坦是新型的ARB类药物,在治疗原发性高血压的过程中安全有效,患者能很好耐受。Objective To evaluate the efficacy and safety of essential hypertension with irbesartan. Methods A randomized,double blind study was carried out on 70 patients with essential hypertension.Patients were divided randomly into two groups and given either irbesartan （irbesartan group） or felodipine （felodipine group ） for 8 weeks. To observe the blood pressure change and adverse reactions. Results Both systolic pressure and diastolic pressure is fallen in the two groups before and after treatment,There was a statistically significant difference （P〈 0.01）.The average reduction in blood pressure readings for the two treatment groups were 74.3% and 71.4% respectively.No significant differences were found between two groups （P〉0.05）. No changes of HR were found throughout the study. No significant changes were found for routine blood examination, liver and renal functions, or electrocardiography after treatment. Conclusion Irbesartan is a new type of ARB,which has effective treatment in essential hypertension.It can be tolerated by the patients.

关 键 词：伊贝沙坦 原发性高血压 临床疗效 安全性 

分 类 号：R972.4[医药卫生—药品]